Literature DB >> 26705962

Association between Hyperprolactinemia and Granulomatous Mastitis.

Anatoly Nikolaev1, Cassann N Blake2, Diane L Carlson2.   

Abstract

Granulomatous mastitis (GM) is a relatively uncommon inflammatory breast lesion with multiple suggested etiologies. Although most GM cases show association with lactation and pregnancy, a minority of cases have been linked to hyperprolactinemia caused by either dopamine antagonist medications or with intracranial lesions, such as pituitary adenoma. The goal of this study is to review the GM cases reported in the literature with a specific emphasis on those cases associated with hyperprolactinemia and prolactinomas and to identify cases of GM seen at the Cleveland Clinic Florida which demonstrate co-occurrences of GM and intracranial lesions. CoPath and Epic data bases at Cleveland Clinic Florida were searched for cases describing inflammatory breast lesions in patients with pituitary pathology. Chart reviews were conducted and pertinent medical history was extracted for case reports. H&E-stained paraffin-embedded sections retrieved from Cleveland Clinic Florida pathology storage were evaluated by light microscopy. Four cases showing a co-occurrence of GM and hyperprolactinemia were consequently identified. A prolactin-secreting pituitary adenoma was present in two of the three GM cases. The third case demonstrated a concomitant craniopharyngioma, which was also associated with a rise in serum prolactin. This phenomenon was presumably attributable to compression, resulting in compromised transport of dopamine to the adenohypophysis and subsequent disinhibition of prolactin secretion by lactotrophs. The fourth patient with GM had a similar history of elevated prolactin. Classical histopathological features of GM were found in all four cases, including noncaseating granulomas, multinucleated giant cells, epithelioid histiocytes, and chronic inflammation. Intriguingly, complete resolution of inflammatory breast lesions along with normalization of prolactin levels occurred following the surgical excision of the craniopharyngioma, suggesting that intracranial lesion-induced hyperprolactinemia might be directly causal in GM. Therefore, the authors would suggest screening for pituitary tumors and evaluate prolactin levels in the workup of GM patients without a recent history of lactation and pregnancy and no other identified etiology.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; granulomatous mastitis; hyperprolactinemia; pituitary adenoma; prolactinoma

Mesh:

Substances:

Year:  2015        PMID: 26705962     DOI: 10.1111/tbj.12552

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  9 in total

Review 1.  Granulomatous mastitis, erythema nodosum and arthritis syndrome: case-based review.

Authors:  Konstantinos Parperis; Savvas Achilleos; Egli Costi; Michail Vardas
Journal:  Rheumatol Int       Date:  2021-03-01       Impact factor: 2.631

2.  Long-Acting Injectable Antipsychotic Use During Pregnancy: A Brief Review and Concise Guide for Clinicians.

Authors:  Sarah A Reinstein; Jessica Cosgrove; Tara Malekshahi; Kristina M Deligiannidis
Journal:  J Clin Psychiatry       Date:  2020-11-24       Impact factor: 4.384

3.  Granulomatous Mastitis and Factors Associated with Recurrence: An 11-Year Single-Centre Study of 113 Patients in Singapore.

Authors:  Qing Ting Tan; Samantha Piaoxue Tay; Mihir Ananta Gudi; Nivedita Vikas Nadkarni; Swee Ho Lim; Esther Wee Lee Chuwa
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

4.  A clinical observation of stage I implant breast reconstruction for mass-like granulomatous lobular mastitis.

Authors:  Chaojie Zhang; Yaqin Wu; Huiling Wang; Jie Zeng; Shanshan Lei; Jie He; Zheng Zeng; Runzhang Wu; Qian Li; Peizhi Fan
Journal:  Gland Surg       Date:  2021-09

5.  Management of granulomatous lobular mastitis: an international multidisciplinary consensus (2021 edition).

Authors:  Qian-Qian Yuan; Shu-Yuan Xiao; Omar Farouk; Yu-Tang Du; Fereshte Sheybani; Qing Ting Tan; Sami Akbulut; Kenan Cetin; Afsaneh Alikhassi; Rami Jalal Yaghan; Irmak Durur-Subasi; Fatih Altintoprak; Tae Ik Eom; Fatih Alper; Mustafa Hasbahceci; David Martínez-Ramos; Pelin Seher Oztekin; Ava Kwong; Cedric W Pluguez-Turull; Kirstyn E Brownson; Shirish Chandanwale; Mehran Habibi; Liu-Yi Lan; Rui Zhou; Xian-Tao Zeng; Jiao Bai; Jun-Wen Bai; Qiong-Rong Chen; Xing Chen; Xiao-Ming Zha; Wen-Jie Dai; Zhi-Jun Dai; Qin-Yu Feng; Qing-Jun Gao; Run-Fang Gao; Bao-San Han; Jin-Xuan Hou; Wei Hou; Hai-Ying Liao; Hong Luo; Zheng-Ren Liu; Jing-Hua Lu; Bin Luo; Xiao-Peng Ma; Jun Qian; Jian-Yong Qin; Wei Wei; Gang Wei; Li-Ying Xu; Hui-Chao Xue; Hua-Wei Yang; Wei-Ge Yang; Chao-Jie Zhang; Fan Zhang; Guan-Xin Zhang; Shao-Kun Zhang; Shu-Qun Zhang; Ye-Qiang Zhang; Yue-Peng Zhang; Sheng-Chu Zhang; Dai-Wei Zhao; Xiang-Min Zheng; Le-Wei Zheng; Gao-Ran Xu; Wen-Bo Zhou; Gao-Song Wu
Journal:  Mil Med Res       Date:  2022-04-26

6.  Pituitary Adenoma and Hyperprolactinemia Accompanied by Idiopathic Granulomatous Mastitis.

Authors:  Sebahattin Destek; Vahit Onur Gul; Serkan Ahioglu; Kursat Rahmi Serin
Journal:  Case Rep Endocrinol       Date:  2017-02-22

7.  Management of idiopathic granulomatous mastitis in lactation: case report and review of the literature.

Authors:  Hannah W Kornfeld; Katrina B Mitchell
Journal:  Int Breastfeed J       Date:  2021-03-04       Impact factor: 3.461

8.  Clinical study on surgical treatment of granulomatous lobular mastitis.

Authors:  Chaojie Zhang; Shanshan Lei; Cheng Kong; Yuanzhen Tan; Xu Dai; Jie He; Qiang Xiao; Shulin Huang
Journal:  Gland Surg       Date:  2019-12

9.  Corynebacterium kroppenstedtii Is an Emerging Cause of Mastitis Especially in Patients With Psychiatric Illness on Antipsychotic Medication.

Authors:  Sally C Y Wong; Rosana W S Poon; Jonathan H K Chen; Herman Tse; Janice Y C Lo; Tak-Keung Ng; Jonathan C K Au; Cindy W S Tse; Ingrid Y Y Cheung; Man-Ting Yuk; Wei-Kwang Luk; Kwok-Yung Yuen
Journal:  Open Forum Infect Dis       Date:  2017-05-06       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.